These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 7562021)

  • 1. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma?
    Migliari R; Muscas G; Solinas A; Melis M; Ionta MT; Massidda B; Usai E
    J Chemother; 1995 Jun; 7(3):240-5. PubMed ID: 7562021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
    Jeon SH; Chang SG; Kim JI
    Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.
    Messing EM; Manola J; Wilding G; Propert K; Fleischmann J; Crawford ED; Pontes JE; Hahn R; Trump D;
    J Clin Oncol; 2003 Apr; 21(7):1214-22. PubMed ID: 12663707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adjuvant chemo-immunotherapy with VBL + INF in renal carcinoma. Long-term results].
    Cocimano V; Marino G; Cevoli R; Marten Perolino R
    Arch Ital Urol Androl; 1993 Apr; 65(2):167-71. PubMed ID: 8330062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interferon and vinblastine in presumably operable metastases of renal carcinoma].
    Pizzocaro G; Piva L; Faustini M; Mangiarotti B; Nicolai N; Salvioni R; Milani A; Zanoni F
    Arch Ital Urol Androl; 1993 Apr; 65(2):177-80. PubMed ID: 8330064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
    Hong SK; Kwak C; Lee SE
    Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?
    Taguchi S; Buti S; Fukuhara H; Otsuka M; Bersanelli M; Morikawa T; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Igawa Y; Homma Y
    PLoS One; 2017; 12(2):e0172341. PubMed ID: 28241027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant immunotherapy in renal cell carcinoma--comparison of interferon alpha treatment with an untreated control.
    Basting R; Corvin S; Händel D; Hinke A; Schmidt D
    Anticancer Res; 1999; 19(2C):1545-8. PubMed ID: 10365142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does radical nephrectomy with immunochemotherapy have any superiority over embolization alone in metastatic renal cell carcinoma? A preliminary report.
    Demirci D; Tatlişen A; Ekmekçioğlu O; Ozcan N; Kaya R
    Urol Int; 2004; 73(1):54-8. PubMed ID: 15263794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
    Doehn Ch; Richter A; Lehmacher W; Jocham D
    Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC).
    Capitanio U; Suardi N; Matloob R; Roscigno M; Abdollah F; Di Trapani E; Moschini M; Gallina A; Salonia A; Briganti A; Montorsi F; Bertini R
    BJU Int; 2014 Aug; 114(2):210-5. PubMed ID: 24854206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent management of renal cell carcinoma].
    Nishio Y; Yoshida O
    Gan To Kagaku Ryoho; 1988 Feb; 15(2):219-23. PubMed ID: 3257677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
    Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
    J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma.
    Gotoh A; Shirakawa T; Hinata N; Wada Y; Hara I; Fujisawa M; Kawabata G; Okada H; Arakawa S; Kamidono S
    Int J Urol; 2004 May; 11(5):257-63. PubMed ID: 15147539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic outcome of 132 cases of laparoscopic radical nephrectomy with intact specimen removal for T1-2N0M0 renal cell carcinoma.
    Hemal AK; Kumar A; Gupta NP; Kumar R
    World J Urol; 2007 Dec; 25(6):619-26. PubMed ID: 17786453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?
    Hernberg M; Muhonen T; Pyrhönen S
    Ann Oncol; 1997 Jan; 8(1):71-7. PubMed ID: 9093710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience.
    Bazzi WM; Sjoberg DD; Feuerstein MA; Maschino A; Verma S; Bernstein M; O'Brien MF; Jang T; Lowrance W; Motzer RJ; Russo P
    J Urol; 2015 Jun; 193(6):1911-6. PubMed ID: 25524244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.